New combo therapy targets esophageal cancer with Radiation-Activated nanoparticles
NCT ID NCT04615013
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 22 times
Summary
This early-phase study tests a new drug called NBTXR3, which is activated by radiation, along with standard chemotherapy for people with esophageal adenocarcinoma. The goal is to find the safest dose and see if this combination can better control the disease. About 24 adults with stage II or III esophageal cancer will receive the drug injected into their tumor, followed by radiation and chemo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.